Bracebridge Capital LLC 13D and 13G filings for Clarus Therapeutics Holdings, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-07-06 4:00 pm Unchanged |
2022-07-06 | 13G | Clarus Therapeutics Holdings, Inc. CRXTQ |
Bracebridge Capital LLC | 2,002,495 54.000% |
0 (Unchanged) |
Filing |
| 2022-02-14 11:34 am Sale |
2021-12-31 | 13G | Clarus Therapeutics Holdings, Inc. CRXTQ |
Bracebridge Capital LLC | 2,002,495 8.300% |
-227,360 (-10.20%) |
Filing |
| 2021-09-17 4:15 pm Purchase |
2021-09-09 | 13G | Clarus Therapeutics Holdings, Inc. CRXTQ |
Bracebridge Capital LLC | 2,229,855 10.300% |
2,229,855 (New Position) |
Filing |